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Abstract: Crotamine is one of the main constituents of the venom of the South American 
rattlesnake Crotalus durissus terrificus. Here we sought to investigate the inflammatory 
and toxicological effects induced by the intrahippocampal administration of crotamine 
isolated from Crotalus whole venom. Adult rats received an intrahippocampal infusion of 
crotamine or vehicle and were euthanized 24 h or 21 days after infusion. Plasma and brain 
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tissue were collected for biochemical analysis. Complete blood count, creatinine,  
urea, glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT),  
creatine-kinase (CK), creatine kinase-muscle B (CK-MB) and oxidative parameters 
(assessed by DNA damage and micronucleus frequency in leukocytes, lipid peroxidation 
and protein carbonyls in plasma and brain) were quantified. Unpaired and paired t-tests 
were used for comparisons between saline and crotamine groups, and within groups (24 h 
vs. 21 days), respectively. After 24 h crotamine infusion promoted an increase of urea, 
GOT, GPT, CK, and platelets values (p ≤ 0.01), while red blood cells, hematocrit and 
leukocytes values decreased (p ≤ 0.01). Additionally, 21 days after infusion crotamine 
group showed increased creatinine, leukocytes, TBARS (plasma and brain), carbonyl 
(plasma and brain) and micronucleus compared to the saline-group (p ≤ 0.01).  
Our findings show that crotamine infusion alter hematological parameters and cardiac 
markers, as well as oxidative parameters, not only in the brain, but also in the blood, 
indicating a systemic pro-inflammatory and toxicological activity. A further scientific 
attempt in terms of preserving the beneficial activity over toxicity is required. 
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1. Introduction 
Snakebites are a public health issue in tropical countries [1]. In Brazil, the South American 
rattlesnake Crotalus durissus Terrificus (Cdt) accounts for 10% of snakebites and constitutes a medical 
problem in the country [2]. Studies with the rattlesnake venoms are carry out mainly to understand the 
mechanism of action of proteins present in these poisons in order to improve the treatment against the 
snakebite accidents. However, toxic components of the Cdt venom, as crotamine, has shown properties 
with potential for therapeutic purposes [3–5].  
Crotamine, a non-enzymatic polypeptide myotoxin, basic character, composed by 42 amino acid 
residues [6], is one of the components of the Cdt venom. This toxin induces depolarization of the skeletal 
muscle membrane by increasing the permeability to sodium ions (Na+), suggesting its binding to  
voltage-gated Na+ channels at the sarcolemma [7]. Despite the potential interaction of crotamine with 
sodium channels, some opposing studies suggested another target for the toxin biological activity [8].  
In the central nervous system (CNS) of rats, crotamine improves the basal release of acetylcholine and 
dopamine [9], which are neurotransmitters strikingly related to the mnemonic process [10,11].  
Considering the crotamine pharmacology, recent studies have shown possible therapeutic 
applicabilities for this toxin. Hernandez-Oliveira e Silva et al. [4] showed the benefits of using 
crotamine in the treatment of myasthenia gravis, an autoimmune disease characterized by a 
dysfunction at the neuromuscular junction, resulting in episodes of muscle weakness and abnormal 
fatigue [12]. In their study, animals treated with crotamine showed progressive and sustained muscle 
contractions, as well as an improvement in exercise tolerance [4]. The application of crotamine 
induced a decrease in the episodes of muscle fatigue compared to animals treated with neostigmine,  
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a common clinical agent used in the myasthenia treatment [4]. Recently, crotamine was proven to be a 
cell-penetrating peptide that can mediate the drug delivery, being cytotoxic to neoplasic cells [3]. 
We recently showed that intrahippocampal infusion of a single dose of crotamine (1 µg/µL;  
1 µL/side) improves after-learning persistence of object recognition and aversive memory [5].  
This result reinforces the potential therapeutic application of crotamine as a novel therapeutic agent to 
treat diseases related to the CNS function, especially in situations in which the loss of cognitive 
function is involved, such as dementias. Apart from the biotechnological perspectives involving 
crotamine, the neurotoxicity induced by the Cdt venom components at central and peripheral nervous 
system has been characterized [13–15]. Thus, despite the wealth of possibilities in terms of the 
possible therapeutic interactions of crotamine at the nervous system, there is few data related to its 
safety assessment evaluation. The aim of this work was to investigate the influence of crotamine on 
inflammatory and toxicological parameters after intrahippocampal administration.  
2. Methods  
2.1. Animals 
Adult male Wistar rats (3 months old) were bought at a registered vivarium. They were housed four 
per cage and maintained under controlled light and environmental conditions (12 h light/12 h dark 
cycle at a temperature of 23 ± 2 °C and humidity of 50 ± 10%) with food and water ad libitum.  
All experiments were conducted in accordance with the “Principles of laboratory animal care” (NIH 
publication No. 80-23, revised 1996) and with the guidelines established by the Institutional Animal 
Care and Use Committee of the Local Institution (IRB #0442012), ensuring that animal number and 
suffering were kept to a minimum. 
To study the systemic effects of single infusion of crotamine in CNS, 24 rats were implanted with 
chronic bilateral guide cannulas in the CA1 region of the hippocampus and divided into two groups: 
controls (n = 12), which received 1 µL/side of vehicle (saline-group), and crotamine (n = 12),  
which received 1 µL/side of crotamine infusion (1 µg/µL; 1 µL/side; crotamine-group). Afterward,  
6 animals from each group were euthanized twenty four hours and 6 twenty one days after crotamine 
or saline intrahippocampal infusion for tissue preparation and biochemical analyses (Figure 1).  
2.2. Drugs 
Ketamine and xylazine were purchased from Sigma Aldrich Brazil (São Paulo, SP, Brazil). 
Crotamine isolated from Cdt venom was a reminiscent stock and was supplied by Dr. Sérgio 
Marangoni from Laboratory of Protein Chemistry (LAQUIP) (UNICAMP, Campinas-SP, Brazil) and 
was prepared daily by dilution in saline immediately before use. The crotamine dose was chosen based 
on previous in vitro [9] and in vivo [5] experiments. Reagents for oxidative parameters analysis were 
purchased from Sigma (St. Louis, MO, USA), and other reagents used in this study were of analytical 
grade and obtained from standard commercial supplier. 
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Figure 1. Schematic representation of the experimental procedures. Rats were submitted to a 
stereotaxic surgery to implant cannulas in the CA1 region of the hippocampus. After 3 days 
of recovery, they are manipulated for 2 days to adapt to the experimenter. Following the 
procedures of cannulas’s implantation and recovery the rats in the saline-group received an 
intrahippocampal infusion of 1 µL/side of vehicle (saline), and rats in the crotamine-group  
1 µL/side of crotamine (1 µg/µL). Afterward, six animals from each group were euthanized 
twenty four hours and six twenty one days after crotamine or saline intrahippocampal 
infusion for tissue preparation and biochemical analyses. 
 
2.3. Surgery and Drug Infusion Procedures 
To implant the rats with indwelling cannulas, they were anesthetized with ketamine and xylazine (i.p., 
75 mg/kg and 10 mg/kg, respectively) and 27-gage cannulas were placed, stereotaxically aimed at CA1 
region of the dorsal hippocampus coordinates (AP-4.2, LL-3.0, VM-2.0 mm), according to Paxinos and 
Watson atlas [16]. The cannulas were affixed to the head bones with dental cement. Animals were 
allowed to recover from surgery for 3 days before submitting them to any other procedure. At the time of 
drug delivery, 30-gage infusion cannulas were tightly fitted into the guides. Infusions (1 µL/side in the 
CA1 region of the hippocampus) were carried out over 60 s with an infusion pump, and the cannulas 
were left in place for 60 additional seconds to minimize backflow. 
2.4. Biochemical Analysis  
Twenty four hours and twenty one days after crotamine intrahippocampal infusion, rats from each 
group were submitted to euthanasia. It permitted collection of tissue (blood and brain) for biochemical 
analyses: hematological parameters, cardiac and oxidative markers. Six rats of each group were 
euthanized in each time. 
The complete blood count (CBC) was performed in an automatic counter Cell-Dyn 3200 
Hematology Analyzer (Abbott Diagnostic, St Clara, CA, USA). Blood creatinine, urea, glutamic 
oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT), and creatine-kinase (CK) 
levels were measured using an automatic analyzer A-25 Biosystems (Biosystems SA, Barcelona, 
Spain) for in vitro diagnostics. Blood creatine kinase-muscle B (CK-MB) was measured using an 
Architect Abbott for in vitro diagnostics.  
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The oxidative parameters (DNA damage and micronucleus frequency in leukocytes [17];  
lipid peroxidation [18] and protein carbonyls [19]) in plasma and brain were measured using 
spectrophotometric methods. For brain analyses, the brain was homogenized in 10 volumes of Tris 
HCl (50 mM, pH 7.4). Afterwards, samples were centrifuged at 2400× g for 20 min, and supernatant 
were used for assay.  
Lipoperoxidation was evaluated by the thiobarbituric acid reactive substance (TBARS) test [18]. 
Samples were rapidly homogenized in 50 mM Tris-HCl, pH 7.5 (1/10, w/v), and centrifuged at  
2500× g for 15 min. One aliquot of supernatant was incubated at 95 °C for 2 h, and the colour reaction 
was measured at 532 nm. Results were expressed as nmol of malondialdehyde per mg protein.  
All plasma and brain biochemical assays were carried out in triplicate. 
2.5. Statistical Analysis 
To compare biochemical markers between saline and crotamine-group unpaired Student t-test was 
used. For comparison of biochemical markers of the same group in different times (24 h and 21 days) a 
paired Student t-test was used. All data were expressed as the mean ± SEM. Differences were 
considered statistically significant when p < 0.01. 
3. Results  
After euthanasia, blood and brain tissue were collected and prepared for analyses of hematological, 
cardiac markers and oxidative parameters. Results of hematological and cardiac parameters after 24 h 
and 21 days of crotamine/saline infusion are present in the Table 1. In the saline-group there were  
no statistical differences between 24 h and 21 days for all parameters analyzed (data presented as  
mean ± SEM of the measurements; Table 1 saline-group). 
Table 1. Results of blood hematological and cardiac parameters. The intrahippocampal 
infusion of crotamine altered some measurements 24 h and 21 days after infusion. Data are 
expressed as mean ± SEM.  
Blood Hematological and 
Cardiac Parameters 
Saline-Group 
Crotamine-Group 
24 h 21 Days 
Creatinine (mg/dL) 0.58 ± 6 × 10−3 0.57 ± 5 × 10−3 0.83 ± 0.01 #,* 
Urea (mg/dL) 45.50 ± 0.89 52.75 ± 1.26 * 34.29 ± 0.30 #,* 
GOT (U/L) 120.00 ± 0.56 142.00 ± 2.22 * 266.10 ± 3.32 #,* 
GPT (U/L) 73.25 ± 0.98 82.75 ± 2.75 * 94.43 ± 1.11 #,* 
CK (U/L) 806.30 ± 4.69 947.00 ± 15.71 * 15 × 102 ± 12.62 #,* 
CK-MB (U/L) 22 × 102 ± 19.11 23 × 102 ± 49.86 24 × 102 ± 0.06 
Red Blood Cells (106/µL) 7.21 ± 0.01 6.66 ± 0.04 * 7.84 ± 0.31 
Hemoglobin (g/dL) 13.58 ± 0.11 13.10 ± 0.16 13.40 ± 0.25 
Hematocrit (%) 40.88 ± 0.18 38.60 ± 0.57 * 37.76 ± 0.50 * 
Leukocytes (103/µL) 58 × 102 ± 57.90 45 × 102 ± 56.41* 93 × 102 ± 253.10 #,* 
Platelets (103/µL) 44 × 104 ± 20 × 102 53 × 104 ± 32 × 102 * 89 × 104 ± 16 × 102 #,* 
* Statistically significant differences (p < 0.01) from saline-group; # Statistically significant differences (p < 0.01) 
from 24 h crotamine-group. 
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The analysis of data related to 24 h post-crotamine infusion showed that toxin induced an increase 
in the values of urea, GOT, GPT, CK and platelets when compared to results from saline-group  
(p < 0.01, Table 1, crotamine-group 24 h). Additionally, toxin infusion induced a decrease in red blood 
cells, hematocrit and leukocytes values. Twenty-one days post-crotamine infusion we observed that the 
values of GOT, GPT, CK, and platelets still were increased and remained different than the saline 
group (p < 0.01, Table 1 crotamine-group 21 days). Also, the hematocrit values still were decreased  
21 days after crotamine infusion (p < 0.01, Table 1 crotamine-group 21 days). For this later group, 
creatinine and leukocytes values also increased and urea values decreased (p < 0.01, Table 1 
crotamine-group 21 days).  
Oxidative parameters showed no changes 24 h-post crotamine infusion. However, 21 days-post 
infusion the values of TBARS (plasma and brain), carbonyl (plasma and brain) and micronucleus were 
increased in the crotamine-group compared to the saline (p < 0.01, Table 2 crotamine-group 21 days). 
In the case of micronucleus, crotamine-infusion induced a further significant increase when compared 
to the toxin 24 h group. 
Table 2. Results of plasma and brain oxidative parameters. The intrahippocampal  
infusion of crotamine altered oxidative parameters 21 days later. Data are expressed as  
mean ± SEM.  
Plasma and Brain Oxidative Parameters Saline-Group 
Crotamine-Group 
24 h 21 Days 
TBARS Plasma (nmol MDA/L) 27.43 ± 0.27 27.43 ± 0.92 50.51 ± 1.37 #,* 
TBARS Brain (nmol MDA/L) 96.13 ± 1.32 97.73 ± 3.62 143.30 ± 4.34 #,* 
Carbonyl Plasma (nmol carbonyl/mg protein) 0.01 ± 2 × 10−4 0.01 ± 4 × 10−4 0.02 ± 6 × 10−4 #,* 
Carbonyl Brain (nmol carbonyl/mg protein) 0.01 ± 3 × 10−4 0.01 ± 5 × 10−4 0.02 ± 7 × 10−4 #,* 
Micronucleus (% frequency) 0.75 ± 0.13 1.00 ± 0.21 1.87 ± 0.19 #,* 
* Statistically significant differences (p < 0.01) from saline-group. # Statistically significant differences  
(p < 0.01) from 24 h-post crotamine-group. 
4. Discussion 
There are about 3000 species of snakes in the world, with 20% of them considered poisonous [20]. 
Annually 19,000 to 22,000 snake accidents occur in Brazil [21]. Most of these accidents are due to the 
Bothrops and Crotalus genus [22], so it is crucial understand the systemic mechanisms involved in the 
toxicity of snake venoms to improve the treatment of the snakebite victims. In this work we show the 
toxic aspects involved with the intrahipocampal infusion of crotamine, especially those related to the 
hematological and biochemical parameters. The aspects related to the safety assessment of crotamine 
are discussed herein. 
Crotamine is a strong basic polypeptide myotoxin consisting of 42 amino acid residues present in 
the venom of the Crotalus durissus terrificus, the South American rattlesnake. Studies have 
investigated its potential therapeutic applicability, although there is a lack of data related to the safety 
assessment of this toxin [4,5]. Mello and Cavalheiro [15] studied the induction of neuropathological 
changes by the infusion of Cdt venom at hippocampus, but they did not investigate the toxicological 
aspects related to the intrahippocampal infusion of Cdt venom. In this work, we have demonstrated 
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that a single intrahippocampal infusion of crotamine induced acute and chronic alterations in 
hematological and cardiac parameters in blood and promoted sub-acute oxidative stress in plasma and 
brain. It is worth mentioning that we recently demonstrated, that a single intrahippocampal infusion of 
crotamine can promote memory persistence [5], highlighting that crotamine could be a potential 
pharmacological tool, especially in case of diseases that involve memory persistence deficits,  
as Alzheimer disease. We now showed that crotamine infusion induced alterations in creatinine, CK, 
leukocytes, platelets, urea, GOT, GPT, red blood cells and hematocrit in the blood; and TBARS, 
carbonyl and micronucleus in the plasma and brain tissue.  
Myotoxins of snake venoms are currently classified into three main groups that constitute structurally 
distinct protein families. Group 1 includes ‘small’ myotoxins (i.e., Crotalus durissus terrificus crotamine, 
Crotalus v. viridis myotoxin a); group 2 includes cardiotoxins; and, group 3 includes PLA2  
myotoxins [23]. The biological activity of myotoxins of snake venoms involves irreversible damage to 
skeletal muscle fibers (myonecrosis) when injected into higher animals. Some myotoxins act locally, 
damaging muscle fibers at the site of injection and its surroundings; others act systemically, causing 
muscle damage at distant sites [24]. Despite the muscular damage (myotoxicity), these toxins can also 
induce other biological activities, which include neurotoxicity and effects such as anticoagulation, 
alterations in platelet aggregation, hypotension, hemolysis and edema [24]. Most of the myotoxins 
involved in deleterious activities against biological tissues are related to the group of PLA2 myotoxins. 
These proteins have evolved from an ancestral PLA2 with digestive function and display a range of 
enzymatic turnover values similar to those digestive enzymes found in pancreatic secretions.  
Despite their weak myotoxic potency, the cellular alterations induced by crotalic venoms are mostly 
related to the activity of non-neurotoxic PLA2 neurotoxins, [23], mainly because their abundance in the 
whole venom. In the case of crotamine, no enzymatic (PLA2) profile is observed, and its 
pharmacological activity is related to the activation of sodium influx at muscle cells [25] and the 
blockage of voltage gated potassium channels (Kv) at nerve tissues [26]. At nerve terminals,  
the activation of voltage-gated sodium channels and/or blockade of Kv by animal neurotoxins 
ultimately cause increase in the influx of calcium to the cell cytosol [27]. In this regard, it is stated that 
the influx of Ca2+ or Na+ ions caused even by subcytolytic concentrations of a snake toxins (or other 
membrane-active factors), could initiate a variety of intracellular processes, including the activation of 
endogenous cellular lipases [23]. Indeed, membrane-active peptides of synthetic or natural origin, free 
of PLA2 contamination, which are not catalytic, induce breakdown of phospholipids and production of 
free fatty acids in skeletal muscle cell cultures, which are compatible with an activation of endogenous 
phospholipase C enzymes [24].  
Therefore, we suggest that calcium homeostasis disturbance induced by intrahippocampal infusion 
of crotamine can account for acute and chronic alterations in hematological and cardiac parameters. 
This reflects the high affinity of these natural molecules with biological tissues and the evolutionary 
ability to diffuse into different organ systems of the victims. Sousa-e-Silva et al. [28] showed that an 
endovenous administration (i.p.) of Cdt venom in dogs increased CK levels; similar effect was 
observed in our experimental conditions, following intrahippocampal infusion of crotamine.  
The increase in the CK levels is generally associated with muscle damage, and can be reinforced by 
the calcium homeostasis disturbance. Here the intrahippocampal infusion of crotamine also decreased 
the leukocytes number after 24 h, but increased it after 21 days after the crotamine infusion.  
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A reasonable explanation for this contradictory modulation is that part of the reminiscent  
crotamine-induced inflammatory process is detectable only in the chronic analysis, but not in the acute 
protocol. Crotamine-infusion also induced an increase in the platelet number. Alterations in the platelet 
number following snake venoms administration is a common fact [29]. Hemorrhagic toxins that cause 
local blood flow impairment, ischemia, and secondary myonecrosis [30], of slow onset, would be 
considered as indirect myotoxic factors in snake venoms [23] 
In addition, 21 days after intrahipocamppal infusion of crotamine we observed the increase of urea 
levels, which is commonly associated with acute renal lesions [28]. GPT and GOT were also elevated in 
rats receiving infusion of crotamine. The alterations in the urea levels provided further information about 
the liver status, revealing a potential hepatotoxic activity of crotamine [31]. The white blood cells, 
leukocytes, were reduced in the acute evaluation following crotamine infusion, as expected [32]. 
Furthermore, the significant alterations in the values of creatinine, urea, GOT, GPT, CK, hematocrit, 
leukocytes and platelets still were present 21 days after crotamine infusion, revealing the irreversible 
kidney, liver and heart long-term damage and the triggering of a prominent chronic inflammatory response.  
Another important contribution of our work was the verification of the increase in the oxidative stress 
parameters followed 21 days after crotamine infusion. This activity was evidenced both in the brain and 
blood tissues and also reflect the long-term alterations induced by crotamine. The oxidative stress occurs 
when there is an imbalance between the generation of oxidant compounds and antioxidant defense 
systems, and by the excessive production of reactive oxygen species (ROS) that serve as a regulatory 
process of the biological homeostasis, but that, in excess, becomes harmful [33]. Da Silva et al. [34] 
demonstrated that different doses of Cdt venom increases lipid peroxidation in the liver of mice, 
corroborating our findings. The increase in lipid peroxidation causes modifications in proteins,  
DNA and cell membrane [35], because the fatty acids present in these structures are susceptible to  
peroxidation [36]. In this sense, Dal Belo et al. [13] showed the ability of the ethanol extract of 
Hypericum brasiliense to improve the cell viability of hippocampal tissue treated with Cdt venom.  
The latter ascribed to quercetin the protective actions of the vegetal extract, a compound that may be the 
key to attenuate the oxidative stress caused by crotamine in further pharmacological studies. 
Our work is also relevant because it brings to light contradictory aspects related to the toxicology of 
crotamine. For example, Pereira et al. investigated the selectivity of crotamine to tumor cells and 
showed that in lower doses (10 μM) this toxin is harmless to normal cells [37]. The authors also 
showed that mice treated for 21 days with crotamine (1 μg/100 μL–2 µM) did not show significant 
alterations on kidney and liver function, as well as in the blood elements [37]. On the contrary,  
our study demonstrated that the intrahippocampal infusion of crotamine induced blood parameter 
alterations and oxidative stress. These differences can be associated with the route of toxin 
administration, which can be peripheral or via direct CNS injection. Boni-Mitake demonstrated that the 
intraperitoneal administration of crotamine was able to reach the liver, kidney, skeletal muscle and,  
to a lesser extent the lungs and spleen of mice [38]. The same authors also verified the native and 
irradiated crotamine biodistribution after intraperitoneal injection and demonstrated that both forms 
have hepatic and renal clearance metabolism and have affinity for the skeletal muscle, but do not cross 
the blood brain barrier [39]. Our experimental design revealed an important aspect about the 
pharmacokinetics of crotamine, demonstrating the ability of this toxin to cross the blood brain barrier, 
as argued by other authors that verified that this toxin is able to cross the blood brain barrier and exert 
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CNS effects [6,14]. Notwithstanding, this assumption is valid as, in our case, a single intrahippocampal 
infusion of crotamine (1 μL/side) was able to alter blood hematological parameters and cardiac 
markers, as well as brain and plasma oxidative parameters, indicating systemic inflammatory and 
toxicological effects. 
5. Conclusions  
Intrahippocampal infusion of crotamine induces toxicity and systemic inflammatory responses in 
peripheral tissues, proving its ability to cross the blood brain barrier. Therefore, it is necessary to find 
alternatives in order to decrease crotamine toxicity. Finally, considering the previous studies revealing 
the therapeutical potential of crotamine upon treatment of cognitive impairments, further studies shall 
be conducted to improve the knowledge about crotamine biodistribution and systemic toxicity. 
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